188 related articles for article (PubMed ID: 24503568)
1. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort.
Habroosh FA; Albrashdi SS; Alsaadi AH; Eatamadi H
Int Ophthalmol; 2024 May; 44(1):222. PubMed ID: 38717530
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.
Lee C; Park JW; Kim YD; Woo KI
Int Ophthalmol; 2024 Apr; 44(1):179. PubMed ID: 38622479
[TBL] [Abstract][Full Text] [Related]
4. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
Pramono LA
Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for the Management of Thyroid-Associated Orbitopathy.
Smith LD; Moscato EE; Seiff SR
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):188-192. PubMed ID: 34293786
[TBL] [Abstract][Full Text] [Related]
6. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
Hwang CJ; Rebollo NP; Mechels KB; Perry JD
Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab.
Rymuza J; Kuś A; Białas-Niedziela D; Turczyńska M; Kęcik D; Bednarczuk T
Endokrynol Pol; 2024; 75(1):117-118. PubMed ID: 38497401
[TBL] [Abstract][Full Text] [Related]
8. A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy.
Wang Y; Zhang S; Zhang Y; Liu X; Gu H; Zhong S; Huang Y; Fang S; Sun J; Zhou H; Fan X
BMC Endocr Disord; 2018 Feb; 18(1):13. PubMed ID: 29463244
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Aqueous Flare in Graves' Ophthalmopathy and its Relationship with Thyroid Hormones, Antibodies, and Clinical Activity Score.
Topcu H; Atik BK; Ozkocak BY; Efe AC; Ulas MG; Cabuk KS
Beyoglu Eye J; 2023; 8(3):208-213. PubMed ID: 37766759
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
Ho TC; Maamari RN; Kossler AL; Sears CM; Freitag SK; Reshef ER; Shinder R; Rootman DB; Diniz SB; Kahana A; Schlachter D; Do TH; Kally P; Turner S; Mokhtarzadeh A; Harrison AR; Hwang CJ; Kim HJ; Avila SA; Thomas DA; Magazin M; Wester ST; Lee WW; Clauss KD; Holds JB; Sniegowski M; Compton CJ; Briggs C; Malik AI; Lucarelli MJ; Burkat CN; Patel LG; Couch SM
Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):150-155. PubMed ID: 36095848
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate for the treatment of thyroid eye disease.
Strianese D; Iuliano A; Ferrara M; Comune C; Baronissi I; Napolitano P; D'Alessandro A; Grassi P; Bonavolontà G; Bonavolontà P; Sinisi A; Tranfa F
J Ophthalmol; 2014; 2014():128903. PubMed ID: 24678411
[TBL] [Abstract][Full Text] [Related]
12. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease.
Sy A; Eliasieh K; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e55-e57. PubMed ID: 27281483
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Graves' ophthalmopathy.
Salvi M
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
[TBL] [Abstract][Full Text] [Related]
14. Commentary: rituximab, adalimumab, etanercept, tocilizumab--are biologics the future for Graves' orbitopathy?
Bartalena L
Ophthalmic Plast Reconstr Surg; 2014; 30(5):420-3. PubMed ID: 25025391
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
[TBL] [Abstract][Full Text] [Related]
16. Medical Treatment of Graves' Orbitopathy.
Salvi M; Campi I
Horm Metab Res; 2015 Sep; 47(10):779-88. PubMed ID: 26361263
[TBL] [Abstract][Full Text] [Related]
17. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
18. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
Bartalena L; Baldeschi L; Boboridis K; Eckstein A; Kahaly GJ; Marcocci C; Perros P; Salvi M; Wiersinga WM;
Eur Thyroid J; 2016 Mar; 5(1):9-26. PubMed ID: 27099835
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and safety of tocilizumab in corticoid refractory Graves' Orbitopathy].
Gómez Rodríguez L; Cárdenas Aranzana MJ; Avilés Mora C
Farm Hosp; 2014 Sep; 38(5):448-50. PubMed ID: 25344141
[No Abstract] [Full Text] [Related]
20. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy.
Campi I; Vannucchi G; Salvi M
Eur J Endocrinol; 2016 Sep; 175(3):R117-33. PubMed ID: 27032693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
